A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

February 26, 2024

Study Completion Date

February 26, 2024

Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
DRUG

mavacamten

mavacamten capsules

Trial Locations (21)

10065

Local Institution - 0012, New York

19104

Local Institution - 0002, Philadelphia

27710

Local Institution - 0003, Durham

29425

Local Institution - 0008, Charleston

30322

Local Institution - 0018, Atlanta

32216

Local Institution - 0020, Jacksonville

33133

Local Institution - 0014, Miami

35249

Local Institution - 0028, Birmingham

49503

Local Institution - 0007, Grand Rapids

60429

Local Institution - 0023, Hazel Crest

60611

Local Institution - 0004, Chicago

70458

Local Institution - 0017, Slidell

73135

Local Institution - 0016, Oklahoma City

84112

Local Institution - 0006, Salt Lake City

85016

Local Institution - 0019, Phoenix

85724

Local Institution - 0011, Tucson

90027

Local Institution - 0005, Los Angeles

94158

Local Institution - 0026, San Francisco

97225

Local Institution - 0010, Portland

97239

Local Institution - 0001, Portland

M5S 1B2

Local Institution - 0034, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY